Swiss Drugmaker Novartis

Swiss drugmaker Novartis has signed an initial agreement to provide manufacturing capacity for Pfizer and Biontech's COVID-19 vaccine, a move aimed at helping boost production as supplies fall shy of demand.

Earlier on Thursday, Bloomberg reported citing people with knowledge of the matter that Swiss drugmaker Novartis AG, which owns three quarters of Novartis India, was considering buying all the shares it didn't already own in the arm.

The Swiss drugmaker impressed doctors at the European Society of Cardiology meeting in Barcelona at the weekend by unveiling strikingly good clinical trial results for the drug, known as LCZ696, in a keenly awaited clinical trial.

Swiss drugmaker Novartis has unveiled strikingly good clinical trial results for a new heart failure drug that might be the biggest pharmaceutical advance in a quarter of century.

Swiss drugmaker Novartis has struck an agreement with Google to develop "smart" contact lenses that would help diabetics track their blood glucose levels or restore the eye's ability to focus.

Novartis has taken Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday.

Dr. Reddy's voluntary recall of lansoprazole delayed release capsules, a generic version of Swiss drugmaker Novartis' drug Prevacid 24 HR, began on January 3, 2014, the FDA said on its website.

The US government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs.

Swiss drugmaker Novartis AG will continue to invest in India, the vice chairman and managing director of the company said today after the Supreme Court dismissed the pharmaceutical major's plea for patent protection of its cancer drug Glivec.

Novartis India Limited, a unit of Swiss drugmaker Novartis AG, will continue to file for patents in India, its vice chairman said on Monday, after the country's top court rejected its plea for patent protection of its drug Glivec.

The Supreme Court on Monday rejected Swiss drugmaker Novartis AG's plea for patent protection of its cancer drug Glivec. The Supreme Court's decision comes after a legal battle that began when Novartis was denied a patent for Glivec in 2006.

The Supreme Court today rejected Swiss drugmaker Novartis AG's plea for a patent protection of its cancer drug Glivec, a move likely to boost the prospects of Indian pharmaceutical firms over foreign ones.

The Supreme Court has dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales. Here is the copy of the full verdict:

The Supreme Court dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.

Shares in drug maker Novartis AG fell sharply after the Supreme Court ruled that the Swiss giant's cancer treatment Glivec does not deserve a patent in India. The ruling was being closely watched by global drugmakers who have been battered by recent intellectual property decisions in India.

Swiss drugmaker Novartis has signed an initial agreement to provide manufacturing capacity for Pfizer and Biontech's COVID-19 vaccine, a move aimed at helping boost production as supplies fall shy of demand.

Earlier on Thursday, Bloomberg reported citing people with knowledge of the matter that Swiss drugmaker Novartis AG, which owns three quarters of Novartis India, was considering buying all the shares it didn't already own in the arm.

The Swiss drugmaker impressed doctors at the European Society of Cardiology meeting in Barcelona at the weekend by unveiling strikingly good clinical trial results for the drug, known as LCZ696, in a keenly awaited clinical trial.

Swiss drugmaker Novartis has unveiled strikingly good clinical trial results for a new heart failure drug that might be the biggest pharmaceutical advance in a quarter of century.

Swiss drugmaker Novartis has struck an agreement with Google to develop "smart" contact lenses that would help diabetics track their blood glucose levels or restore the eye's ability to focus.

Novartis has taken Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday.

Dr. Reddy's voluntary recall of lansoprazole delayed release capsules, a generic version of Swiss drugmaker Novartis' drug Prevacid 24 HR, began on January 3, 2014, the FDA said on its website.

The US government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs.

Swiss drugmaker Novartis AG will continue to invest in India, the vice chairman and managing director of the company said today after the Supreme Court dismissed the pharmaceutical major's plea for patent protection of its cancer drug Glivec.

Novartis India Limited, a unit of Swiss drugmaker Novartis AG, will continue to file for patents in India, its vice chairman said on Monday, after the country's top court rejected its plea for patent protection of its drug Glivec.

The Supreme Court on Monday rejected Swiss drugmaker Novartis AG's plea for patent protection of its cancer drug Glivec. The Supreme Court's decision comes after a legal battle that began when Novartis was denied a patent for Glivec in 2006.

The Supreme Court today rejected Swiss drugmaker Novartis AG's plea for a patent protection of its cancer drug Glivec, a move likely to boost the prospects of Indian pharmaceutical firms over foreign ones.

The Supreme Court has dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales. Here is the copy of the full verdict:

The Supreme Court dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.

Shares in drug maker Novartis AG fell sharply after the Supreme Court ruled that the Swiss giant's cancer treatment Glivec does not deserve a patent in India. The ruling was being closely watched by global drugmakers who have been battered by recent intellectual property decisions in India.